secwatch.observer — SEC 8-K summary
======================================

Issuer:     FRACTYL HEALTH, INC. (GUTS)
CIK:        0001572616
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058615
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fractyl Health Q1 net loss $3.3M; cash $121.4M; Remain-1 pivotal study H2 2024
------------------------------------------------------------------------------

- Net loss $3.3M vs $11.9M YoY; includes $17.1M non-cash gain from fair value changes.
- Cash and cash equivalents $121.4M as of March 31, 2024; expected to fund operations through 2025.
- Expects to initiate Remain-1 pivotal study for weight maintenance after GLP-1 discontinuation in H2 2024.
- Topline data from Revitalize-1 pivotal T2D study anticipated in Q4 2024; enrollment completion expected Q2 2024.
- Appointed Adrian Kimber as Chief Commercial Officer; Germany registry study shows HbA1c reduction >1% and weight loss >15 lbs at 3 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/0000950170-24-058615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1572616/000095017024058615/guts-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer